(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).
not rated yet |
0
A pioneering surgical blood salvage technology developed at the University of Strathclyde, Glasgow, is set to transform the way major surgery is carried out by reducing blood loss in patients.
not rated yet |
0
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is published in The New England ...
not rated yet |
0
Common variants of the ApoE gene are strongly associated with the risk of developing late-onset Alzheimer's disease, but the gene's role in the disease has been unclear. Now, researchers funded by the National ...
5 / 5 (5) |
0
|
Many children with Crohn's disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for ...
not rated yet |
0
(AP) -- Italy's health ministry on Thursday asked hospitals to track down women who received silicone breast implants made by a suspect French company due to concerns the implants may be unsafe.
not rated yet |
0
A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.
not rated yet |
0
|
Imagine a single drug that would treat most, if not all, autoimmune disorders, such as asthma, inflammatory bowel disease, and Lupus. That might not be so hard to do thanks to a team of researchers who have discovered a molecule ...
5 / 5 (2) |
0
|
In Western societies, atherosclerosis of the arteries is one of the leading causes of death. Chronic, localized inflammation of the blood vessel wall facilitates the growth of fibrous plaques, which leads to narrowing or ...
not rated yet |
0
|
